Amin Sharifan

57224116591

Publications - 3

Global burden of amphetamine, cannabis, cocaine and opioid use in 204 countries, 1990–2023: a Global Burden of Disease Study

Muhammad Suleman Masood Ali Shaikh Jiseung Kang Sa’ed H. Zyoud Chuanhua Yu Naohiro Yonemoto Manish Vinayak Georgios Ioannis Verras Siavash Vaziri Hyeon Jin Kim Min Seo Kim Magdalena Zielińska Bin Zhu Paul Yip Dehui Yin Renjulal Yesodharan Tommi Juhani Vasankari Joe Varghese Jef Van den Eynde Munkhtuya Tumurkhuu Abdul Rohim Tualeka Evangelia Eirini Tsermpini Alexander C. Tsai Samuel Joseph Tromans Aristidis Tsatsakis Atta Ullah Masayuki Teramoto Mohamad Hani Temsah Reem Temsah Yonas Getaye Tefera Vinay Suresh Vetriselvan Subramaniyan Dan J. Stein Chandrashekhar T. Sreeramareddy Joan B. Soriano Roman Shrestha Sunil Shrestha Pavanchand H. Shetty Premalatha K. ShettyS Minale Tareke Seyed Afshin Shorofi Soroush Soraneh Amin Sharifan Ujjawal Sharma Manoj Sharma Javad Sharifi Rad Alfiya Shamsutdinova Ireneous N. Soyiri Aminu Shittu Sunder Sham Anthony Zhong Jingya Zhang Haijun Zhang Mohammed G.M. Zeariya Aurora Zanghì Marcos Roberto Tovani-Palone Jovana Todorovic Marco Torrado Tenaw Yimer Tiruye Kavumpurathu Raman Thankappan Baljinder Singh Jasvinder A. Singh Luís Manuel Lopes Rodrigues Silva João Pedro Silva Inga Dora Sigfusdottir Emmanuel Edwar Siddig Mahabalesh Shetty Ali Sheidaei Vishal Sharma Angga Wilandika Nuwan Darshana Wickramasinghe Yuan Pang Wang Mandaras Tariku Walde Isidora S. Vujcic Shu Wang Asokan Govindaraj Vaithinathan Saeed Ullah Nguyen Tran Minh Duc Thang Huu Tran Mircea Tampa Seyyed Mohammad Tabatabaei Rafael Tabarés-Seisdedos Lukasz Szarpak Chandan Kumar Swain Payam Tabaee Damavandi Alireza Shakeri Masood Ali Shaikh Aniefiok John Udoakang Matiwos Soboka Mehran Shams-Beyranvand Y. Waheed Farrukh Sobia Anna Aleksandrovna Skryabina Valentin Yurievich Skryabin Surjit Singh Fathiah Zakham Hadiza Yusuf Zwanden Sule Yahaya Harmanjit Singh Sa’ed H. Zyoud Asokan Govindaraj Vaithinathan Paramdeep Singh Shu Wang Ker Kan Tan Pavanchand H. Shetty Premalatha K. ShettyS Marco Torrado

Publication Name: Nature Medicine

Publication Date: 2026-02-01

Volume: 32

Issue: 2

Page Range: 527-544

Description:

Drug use disorders (DUDs) are emerging global public health challenges. Here we investigated the global and regional estimates of the prevalence and burden of DUDs, including amphetamine, cannabis, cocaine and opioid use disorders, from 1990 to 2023 for 204 countries and territories by using the Global Burden of Disease Study 2023. Overall, trends in global age-standardized disability-adjusted life-years of DUDs increased from 169.3 (95% uncertainty interval (95% UI), 134.4–203.9) per 100,000 people in 1990 to 212.0 (95% UI, 179.2–245.6) in 2023. In 2023, both prevalence and burden of DUDs were higher in high-income countries, particularly in the USA. The most prevalent DUDs in 2023 were cannabis use disorder (age-standardized prevalence, 270.8 (95% UI, 201.7–350.0) per 100,000 people) and opioid use disorder (205.9 (95% UI, 178.7–235.0)). Particularly, opioid use disorder showed a nearly twofold increase in prevalence and burden between 1990 and 2023. In 2023, compared with countries where cannabis use was illegal, countries permitting both recreational and medical cannabis use had higher prevalence rates for all types of DUDs. Proactive and effective policies are essential to mitigate the increasing global burden of DUDs.

Open Access: Yes

DOI: 10.1038/s41591-025-04137-0

Author Correction: Global burden of amphetamine, cannabis, cocaine and opioid use in 204 countries, 1990–2023: a Global Burden of Disease Study (Nature Medicine, (2026), 32, 2, (527-544), 10.1038/s41591-025-04137-0)

Luís Manuel Lopes Rodrigues Silva Ireneous N. Soyiri Aminu Shittu Ker Kan Tan Siavash Vaziri Farrukh Sobia Seyed Afshin Shorofi Y. Waheed Alexander C. Tsai Abdul Rohim Tualeka Fathiah Zakham Lukasz Szarpak Ujjawal Sharma Mircea Tampa Nuwan Darshana Wickramasinghe Manoj Sharma Marco Torrado Surjit Singh Baljinder Singh Emmanuel Edwar Siddig Dehui Yin Seyyed Mohammad Tabatabaei Isidora S. Vujcic Evangelia Eirini Tsermpini Yonas Getaye Tefera Ali Sheidaei Mohamad Hani Temsah Sunil Shrestha Matiwos Soboka Marcos Roberto Tovani-Palone Vetriselvan Subramaniyan Samuel Joseph Tromans Aurora Zanghì Hadiza Yusuf Minale Tareke Mehran Shams-Beyranvand Tenaw Yimer Tiruye Inga Dora Sigfusdottir Bin Zhu Zwanden Sule Yahaya Muhammad Suleman Nguyen Tran Minh Duc Tommi Juhani Vasankari Renjulal Yesodharan Paramdeep Singh Kavumpurathu Raman Thankappan Masood Ali Shaikh Min Seo Kim João Pedro Silva Naohiro Yonemoto Chuanhua Yu Chandrashekhar T. Sreeramareddy Harmanjit Singh Atta Ullah Jiseung Kang Shu Wang Haijun Zhang Aniefiok John Udoakang Saeed Ullah Alireza Shakeri Anna Aleksandrovna Skryabina Reem Temsah Masayuki Teramoto Amin Sharifan Georgios Ioannis Verras Valentin Yurievich Skryabin Mohammed G.M. Zeariya Joe Varghese Soroush Soraneh Angga Wilandika Mandaras Tariku Walde Anthony Zhong Jef Van den Eynde Vishal Sharma Sunder Sham Hyeon Jin Kim Vinay Suresh Thang Huu Tran Manish Vinayak Jingya Zhang Magdalena Zielińska Asokan Govindaraj Vaithinathan Paul Yip Chandan Kumar Swain Munkhtuya Tumurkhuu Dan J. Stein Javad Sharifi Rad Sa’ed H. Zyoud Roman Shrestha Pavanchand H. Shetty Payam Tabaee Damavandi Premalatha K. ShettyS Aristidis Tsatsakis Alfiya Shamsutdinova Rafael Tabarés-Seisdedos Jovana Todorovic Mahabalesh Shetty Joan B. Soriano Jasvinder A. Singh Yuan Pang Wang

Publication Name: Nature Medicine

Publication Date: 2026-01-01

Volume: Unknown

Issue: Unknown

Page Range: Unknown

Description:

Correction to: Nature Medicinehttps://doi.org/10.1038/s41591-025-04137-0, published online 16 January 2026. In the original version of this article, errors and omissions were identified in the Competing Interests statements of several authors among the GBD 2023 Substance Use Collaborators. Following a comprehensive review of all competing interest declarations, corrections were required for nine authors. The competing interests statement for S. Afzal was incomplete. The statement has been amended to include grants or contracts from the Dean Office, Institute of Public Health Lahore. The competing interests statement for L. Monasta was incomplete. The statement has been amended to include support for the present manuscript from the Italian Ministry of Health to the Institute for Maternal and Child Health – IRCCS Burlo Garofolo, with payments made to the institution under project RC 34/2027; all outside the submitted work. The competing interests statement for J.P.S. was incomplete. The statement has been amended to include support for the present manuscript from the Portuguese Foundation for Science and Technology, including payment of salary under contract reference 2021.01789.CEECIND/CP1662/CT0014; all outside the submitted work. The competing interests statement for L.M.L.R.S. contained inaccuracies regarding the sources of grants or contracts. The statement has been corrected to accurately reflect support received from SPRINT – Sport Physical Activity and Health Research & Innovation Center, Polytechnic of Guarda, 6300-559 Guarda, Portugal and RISE–Health, Faculty of Health Sciences, University of Beira Interior, 6201-506 Covilhã, Portugal. The competing interests statement for J.A.S. was incomplete. The statement has been amended to include stock or stock options in Atyr Pharmaceuticals. The competing interests statement for A.C.T. contained an incorrect NIH grant number. The grant number has been corrected from K34DA061696 to K24DA061696. The competing interests statements for B. Oancea, K. Krishan, and I. N. Soyiri were omitted from the version of this article initially published. The statements have now been added and read as follows: “B.O. reports grants from the Core Program within the Romanian National Research, Development, and Innovation Plan 2022–2027, carried out with the support of MRID, project no. 23020101 (SIA-PRO), contract no. 7N/2022, and project PNRR-I8 no. 842027778, contract no. 760096. K. Krishan reports non-financial support from the UGC Centre of Advanced Study (CAS II), awarded to the Department of Anthropology, and support from the RUSA 2.0 grant awarded by the Ministry of Education to Panjab University, Chandigarh, India; all outside the submitted work. I.N.S. reports a leadership or fiduciary role in another board, society, committee, or advocacy group, paid or unpaid, as a trustee of the Citizens Advice Bureau for Hull & East Riding, United Kingdom.” These errors have now been corrected in the HTML and PDF versions of the article. No other parts of the article have been changed.

Open Access: Yes

DOI: 10.1038/s41591-026-04513-4

Global, regional, and national trends in routine childhood vaccination coverage from 1980 to 2023 with forecasts to 2030: a systematic analysis for the Global Burden of Disease Study 2023

Catherine Bisignano Ashley A. Harris Amanda E. Smith Paulina A. Lindstedt Simeon Okechukwu Ajakwe Olivia D. Nesbit Taylor Noyes Noga Shalev Latera Tesfaye Olana Catherine M. Antony Nancy Fullman Sharareh Eskandarieh Mushood Ahmed Naveed Ahmed Rana Kamal Abu Farha Kamoru Ademola Adedokun Nurudeen A. Adegoke Aanuoluwapo Adeyimika Afolabi Giuseppina Affinito Dolapo Emmanuel Ajala Eman Abu-Gharbieh Reed J.D. Sorensen Chun Wei Yuan Stein Emil Vollset Stephen S. Lim Jonathan F. Mosser Andy Stergachis Farbod Khosravi Sonali Kochhar Armita Abedi Usha Adiga Mitra Abbasifard Mohammad Amin Aalipour Faezeh Abbaspour Tomislav Mestrovic Dariush Abtahi Ripon Kumar Adhikary Mohd Adnan Aqeel Ahmad Simon I. Hay Abdollah Jafarzadeh Williams Agyemang-Duah Hana J. Abukhadijah Danish Ahmad Amin Sharifan Rotimi Felix Afolabi Saira Afzal Emad M. Abdallah Samar Abd Elhafeez Meqdad Saleh Ahmed Muktar Beshir Ahmed Syed Anees Ahmed Suneth Buddhika Agampodi Khurshid Ahmad Tauseef Ahmad Sepehr Aghajanian Ayman Ahmed Ramy Mohamed Ghazy Meriem Abdoun Salahdein Aburuz Lucas Guimarães Abreu Alireza Shakeri Qorinah Estiningtyas Sakilah Adnani Emily Haeuser Sam Byrne Jason Nguyen Catalina Raggi Susan A. McLaughlin Hedayat Abbastabar Rana Kamal Abu Farha Sherief Abd-Elsalam Dmitry Abramov Adam Abdullahi Faezeh Abbaspour Reda Abdel-Hameed Samar Abd ElHafeez Atef Abdelkader Deldar Morad Abdulah Haroon Ahmed Lisa C. Adams Toufik Abdul-Rahman Constanza Elizabeth Aguilera Arriagada Mahsa Ahadi Rabbiya Ahmad Shoaib Ahmad Asrat Agalu Abejew Abdu A. Adamu Juliana Bunmi Adetunji Kulmira Abdykerimova Rahim Abo Kasem Nagah M. Abourashed Mohamed Abouzid Roberto Ariel Abeldaño Zuñiga Juan Manuel Acuna Anirudh Balakrishna Acharya Meshack Achore Ousman Adal Habeeb Abiodun Afolabi Hasan Aalruz Arman Abdous Auwal Abdullahi Bilyaminu Abubakar David Adedia Syed Hani Abidi Olumide Abiodun Hassan Abolhassani Richard Gyan Aboagye Ulric Sena Abonie Abdullahi Tunde Aborode Wakgari Mosisa Abdisa Oyelola A. Adegboye Mohammad Mahdi Bastan Dhiraj Motilal Agarwal Tajudeen Adesanmi Adebisi Oluwatobi E. Adegbile Olumide Thomas Adeleke Mache Tsadik Adhana Molalegne Bitew Feven Sahle Gebre Leticia Akua Adzigbli Alireza Mirkheshti Sohrab Salimi Seyed Mohammad Seyed Alshohadaei Hafsa Zia Gizachew Taddesse Akalu Jiawei He Prince Owusu Adoma Dorsa Salabat Mohamed Jalloh Vafa Rahimi-Movaghar Sina Shool Melika Jameie Jafar Karami Farzad Kompani Mohammad Ali Mansournia Abdolreza Mohammadi Amin Mohsenzadeh Aleksandr Y. Aravkin Omid Dadras Iman M. Talaat Ali H. Mokdad Xiaochen Dai Lalit Dandona Rakhi Dandona Sara Bagheri Fereshteh Baghizadeh Mahdis Bayat Minoo Heidari Almasi Ali Asghar Kolahi Ali Nikoobar Mohammad Mahdi Rashidi Firoozeh Madadi Mehdi Safari Mastooreh Sagharichi Maryam Shayan Georgia Smith Samuel James Herold Annie Haakenstad Christopher J.L. Murray Zahra Siavashpour Mohsen Rezaeian Shakiba Ghasemi Assl Atakan Orscelik Yigit Can Senol Michael Zastrozhin Hannah Elizabeth Robinson-Oden Amin Azizan Nazila Rezaei Pegah Salimi Pormehr Amin Sedigh Farshad Shahkarami Kazem Ghaffari Ghazal Arjmand Mahsa Asadi Anar Rasoul Ebrahimi Seyed Ataollah Madinezad Behnaz Niroomand Seyed Kiarash Sadat Rafiei Antonio Olivas-Martinez

Publication Name: Lancet

Publication Date: 2025-07-19

Volume: 406

Issue: 10500

Page Range: 235-260

Description:

Background: Since its inception in 1974, the Essential Programme on Immunization (EPI) has achieved remarkable success, averting the deaths of an estimated 154 million children worldwide through routine childhood vaccination. However, more recent decades have seen persistent coverage inequities and stagnating progress, which have been further amplified by the COVID-19 pandemic. In 2019, WHO set ambitious goals for improving vaccine coverage globally through the Immunization Agenda 2030 (IA2030). Now halfway through the decade, understanding past and recent coverage trends can help inform and reorient strategies for approaching these aims in the next 5 years. Methods: Based on the Global Burden of Diseases, Injuries, and Risk Factors Study 2023, this study provides updated global, regional, and national estimates of routine childhood vaccine coverage from 1980 to 2023 for 204 countries and territories for 11 vaccine-dose combinations recommended by WHO for all children globally. Employing advanced modelling techniques, this analysis accounts for data biases and heterogeneity and integrates new methodologies to model vaccine scale-up and COVID-19 pandemic-related disruptions. To contextualise historic coverage trends and gains still needed to achieve the IA2030 coverage targets, we supplement these results with several secondary analyses: (1) we assess the effect of the COVID-19 pandemic on vaccine coverage; (2) we forecast coverage of select life-course vaccines up to 2030; and (3) we analyse progress needed to reduce the number of zero-dose children by half between 2023 and 2030. Findings: Overall, global coverage for the original EPI vaccines against diphtheria, tetanus, and pertussis (first dose [DTP1] and third dose [DTP3]), measles (MCV1), polio (Pol3), and tuberculosis (BCG) nearly doubled from 1980 to 2023. However, this long-term trend masks recent challenges. Coverage gains slowed between 2010 and 2019 in many countries and territories, including declines in 21 of 36 high-income countries and territories for at least one of these vaccine doses (excluding BCG, which has been removed from routine immunisation schedules in some countries and territories). The COVID-19 pandemic exacerbated these challenges, with global rates for these vaccines declining sharply since 2020, and still not returning to pre-COVID-19 pandemic levels as of 2023. Coverage for newer vaccines developed and introduced in more recent years, such as immunisations against pneumococcal disease (PCV3) and rotavirus (complete series; RotaC) and a second dose of the measles vaccine (MCV2), saw continued increases globally during the COVID-19 pandemic due to ongoing introductions and scale-ups, but at slower rates than expected in the absence of the pandemic. Forecasts to 2030 for DTP3, PCV3, and MCV2 suggest that only DTP3 would reach the IA2030 target of 90% global coverage, and only under an optimistic scenario. The number of zero-dose children, proxied as children younger than 1 year who do not receive DTP1, decreased by 74·9% (95% uncertainty interval 72·1–77·3) globally between 1980 and 2019, with most of those declines reached during the 1980s and the 2000s. After 2019, counts of zero-dose children rose to a COVID 19-era peak of 18·6 million (17·6–20·0) in 2021. Most zero-dose children remain concentrated in conflict-affected regions and those with various constraints on resources available to put towards vaccination services, particularly sub-Saharan Africa. As of 2023, more than 50% of the 15·7 million (14·6–17·0) global zero-dose children resided in just eight countries (Nigeria, India, Democratic Republic of the Congo, Ethiopia, Somalia, Sudan, Indonesia, and Brazil), emphasising persistent inequities. Interpretation: Our estimates of current vaccine coverage and forecasts to 2030 suggest that achieving IA2030 targets, such as halving zero-dose children compared with 2019 levels and reaching 90% global coverage for life-course vaccines DTP3, PCV3, and MCV2, will require accelerated progress. Substantial increases in coverage are necessary in many countries and territories, with those in sub-Saharan Africa and south Asia facing the greatest challenges. Recent declines will need to be reversed to restore previous coverage levels in Latin America and the Caribbean, especially for DTP1, DTP3, and Pol3. These findings underscore the crucial need for targeted, equitable immunisation strategies. Strengthening primary health-care systems, addressing vaccine misinformation and hesitancy, and adapting to local contexts are essential to advancing coverage. COVID-19 pandemic recovery efforts, such as WHO's Big Catch-Up, as well as efforts to bolster routine services must prioritise reaching marginalised populations and target subnational geographies to regain lost ground and achieve global immunisation goals. Funding: The Bill & Melinda Gates Foundation and Gavi, the Vaccine Alliance.

Open Access: Yes

DOI: 10.1016/S0140-6736(25)01037-2